The peptide the internet calls a “Wolverine healing factor.” Here is what 100+ animal studies actually show — and why human evidence is still almost nonexistent.
BPC-157 stands for Body Protection Compound-157. It is a synthetic peptide consisting of 15 amino acids, derived from a protein found naturally in human gastric juice. The “157” refers to its position in the sequence of that parent protein.
It is classified as a gastric pentadecapeptide — “gastric” because it was isolated from stomach secretions, and “pentadecapeptide” because it contains exactly 15 amino acid residues. The specific sequence is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
In the body, gastric juice contains a larger protein called BPC (Body Protection Compound) that appears to play a role in gut mucosal protection and repair. BPC-157 is a stable fragment of this protein — researchers synthesized it because the full protein is too unstable to study effectively. The fragment retains the biological activity while being far more practical for research.
BPC-157 is not FDA-approved for any indication. It is available as a research chemical and through compounding pharmacies. It is one of the most discussed peptides in the biohacking and performance-enhancement communities.
These are real claims pulled from Reddit threads, peptide forums, influencer content, and paid “courses.” They range from exaggerated to outright false.
BPC-157 heals everything — torn tendons, ligaments, gut, brain injuries, you name it. It is basically a regeneration cheat code.
Tendons, gut lining, brain trauma, liver damage, muscle tears — there is nothing BPC-157 cannot repair. One peptide to rule them all.
It is completely safe with no known side effects. Your body already makes it, so how could it possibly be harmful?
Skip the needles. Oral BPC-157 is just as effective as injectable — capsules, sublingual tablets, it all gets absorbed the same.
You will feel the difference within 48-72 hours. Some people report pain reduction after a single injection.
Just take some BPC and it works. The dose does not really matter — 100mcg, 500mcg, whatever you can get.
BPC-157 is basically approved. Clinics prescribe it openly, so it must be regulated and safe.
Combine BPC-157 with TB-500 for the "Wolverine Stack" — double the peptides, double the healing. Everyone on Reddit does it.
Real mechanisms, real studies, real limitations. No spin.
The majority of BPC-157 research comes from one lab (Sikiric et al. at the University of Zagreb). Over 100 rat studies show consistent wound healing, tendon repair, and gastrointestinal mucosal protection. The mechanisms are real and well-characterized. However, single-lab dominance and absence of independent replication in humans is a significant caveat.
BPC-157 promotes angiogenesis (formation of new blood vessels), upregulates growth factor receptors (including VEGF, EGF, and FGF), and modulates the nitric oxide system. These are legitimate biological pathways involved in tissue repair. The molecular biology is real — the question is whether these mechanisms translate to meaningful clinical outcomes in humans at achievable doses.
As of 2026, there are virtually no published randomized controlled trials (RCTs) of BPC-157 in humans. The vast majority of evidence is preclinical (rats with surgically induced injuries). Dosing, timing, bioavailability, and side effect profiles in humans remain largely uncharacterized by formal research.
The ENORM trial is the first significant attempt at a human RCT for BPC-157 in inflammatory bowel disease (IBD). It represents a critical bridge between decades of animal data and actual clinical evidence. Results are still pending, but the trial's existence signals that the scientific community is taking BPC-157 seriously enough to invest in proper human studies.
BPC-157 is a 15-amino-acid peptide. Peptides are generally broken down by digestive enzymes, which is why most are injected. Some researchers (including the Sikiric group) argue BPC-157 has unusual gastric stability since it was originally isolated from gastric juice. However, systemic bioavailability of oral BPC-157 vs subcutaneous injection has not been rigorously compared in humans. Oral may work for gut-local effects; systemic effects likely require injection.
The most commonly reported community protocol is 250-500mcg injected subcutaneously once or twice daily, typically near the injury site. This dosing is extrapolated from rat studies using body surface area scaling — it is an educated guess, not an established therapeutic dose. Higher doses have not been shown to be more effective, and there is no human dose-response curve.
Reported side effects in the community are generally mild: injection site irritation, mild nausea, dizziness, and occasional headaches. No serious adverse events have been widely reported. However, the absence of evidence is not evidence of absence — without systematic safety monitoring in human trials, long-term effects remain unknown. People with active cancers should exercise particular caution given BPC-157's angiogenic properties.
BPC-157 is classified as a research chemical. It is not FDA-approved for any indication. The FDA issued a warning letter in 2022 regarding peptide products including BPC-157. Clinics that prescribe it do so off-label through compounding pharmacies. This does not mean it is dangerous, but it does mean regulatory oversight of purity and dosing is limited.
BPC-157 is one of the most promising peptides in preclinical research. The mechanisms are real — angiogenesis, growth factor upregulation, nitric oxide modulation — and the animal data is unusually consistent across dozens of injury models. But promising preclinical data is not the same as proven clinical efficacy. Almost everything we know comes from rat studies, mostly from a single research group. There are no completed human RCTs, no established human dosing, and no long-term safety data in people. The ENORM trial in IBD represents a genuine step toward human evidence, but results are not yet available. If you choose to use BPC-157, you are essentially participating in an uncontrolled self-experiment — which makes meticulous tracking of your doses, symptoms, side effects, and outcomes not just helpful, but essential.
The research that matters most. These are the papers the BPC-157 evidence base is built on.
Comprehensive review of 100+ BPC-157 animal studies covering mechanisms, organ systems, and dose ranges.
Details the angiogenesis and growth factor mechanisms underlying BPC-157's tissue repair effects.
Demonstrated accelerated healing of transected Achilles tendons and medial collateral ligaments in rats.
Systematic review consolidating evidence for BPC-157 in soft tissue healing. Confirmed strong preclinical evidence but noted absence of human trials.
First major randomized controlled trial of BPC-157 in humans. Targets IBD patients. Results pending as of 2026.
What people actually use. These are community-reported protocols, not clinically validated regimens.
250-500mcg injected once or twice daily, typically near the site of injury or inflammation. Rotate injection sites. Most common cycle: 4-6 weeks on, 2-4 weeks off. Reconstitute lyophilized powder with bacteriostatic water.
This is the most commonly reported route in the community and the closest analog to how BPC-157 is administered in animal studies.
500-1000mcg taken orally once or twice daily, usually on an empty stomach. Some use sublingual tablets for partial buccal absorption. Typical cycle: 4-8 weeks.
May be effective for gut-local issues (IBS, gastric ulcers, gut lining repair). Systemic bioavailability through oral dosing is debated and likely lower than injection.
500mcg 2x/day for 2-4 weeks (loading phase), then 250mcg 1x/day for 2-4 weeks (maintenance). Some users cycle continuously with periodic breaks.
There is no published human data supporting loading vs. maintenance dosing. This protocol is community-derived from anecdotal reporting.
If you are using BPC-157, tracking these metrics is how you turn self-experimentation into useful data.
Log daily pain levels, mobility, and specific symptoms at the target site. Use a 0-10 scale consistently. This is your primary signal for whether the compound is doing anything.
Track where you inject on a body map to ensure proper rotation and identify any site-specific reactions. Repeated injections in the same spot increase the risk of lipodystrophy and local irritation.
Take consistent photos of the target area (same lighting, angle, time of day) weekly. Visual progress is often more reliable than subjective pain reports.
Record exact dose, time of injection, and whether you injected locally (near the injury) or systemically (abdomen, deltoid). This data is critical for identifying what works for your specific situation.
Log any nausea, headache, dizziness, injection site redness, or unusual symptoms — even mild ones. Early detection of patterns lets you adjust protocol before problems escalate.
If you are using BPC-157 for gut healing, consider tracking inflammatory markers (CRP, ESR) and relevant panels before and during use. There is no BPC-157-specific blood test, but downstream markers may shift.
Often discussed alongside BPC-157. Each has its own evidence profile.
Log every dose, map your injection sites, track your symptoms, and let your data show you what actually works. BPC-157 is an experiment — run it like one.
Get Started Free →